Plasma therapy likely to be dropped from COVID-19 clinical management guidelines after doubts over its effectiveness


PTI, May 17, 2021, 1:09 PM IST

New Delhi: Plasma therapy on COVID-19 patients has not been found effective in reducing the progression to severe disease or death and is likely to be dropped from the clinical management guidelines, sources said.

In a meeting of the ICMR-National Task Force for COVID-19 on Friday, all members were in favour of removing the use of convalescent plasma from the Clinical Guidance for Management of Adult COVID-19 Patients citing its ineffectiveness and inappropriate use in several cases, they said.

The Indian Council of Medical Research (ICMR) will issue an advisory on the matter soon, they said.

The present guidelines allow “off label” use of plasma therapy at the stage of early moderate disease, that is, within seven days of the onset of symptoms and if there is the availability of a high titre donor plasma.

The decision to remove it from the guidelines comes in the backdrop of some clinicians and scientists writing to Principal Scientific Advisor K VijayRaghavan cautioning against the “irrational and non-scientific use” of convalescent plasma for COVID-19 in the country.

In the letter, which was also marked to ICMR chief Balram Bhargava and AIIMS Director Randeep Guleria, public health professionals alleged that the current guidelines on plasma therapy are not based on existing evidence and pointed out some very early evidence that indicates a possible association between emergence of variants with lower susceptibility to neutralising antibodies in immunosuppressed” people given plasma therapy.

This raises the possibility of more virulent strains developing due to irrational use of plasma therapy which can fuel the pandemic, according to the letter signed by vaccinologist Gagandeep Kang, surgeon Pramesh C S and others.

“We are writing to you as concerned clinicians, public health professionals and scientists from India about the irrational and non-scientific use of convalescent plasma for COVID-19 in the country. This has stemmed from guidelines issued by government agencies, and we request your urgent intervention to address the issue which can prevent harassment of COVID-19 patients, their families, their clinicians and COVID-19 survivors,” said the letter.

“The current research evidence unanimously indicates that there is no benefit offered by convalescent plasma for treatment of COVID-19. However, it continues to be prescribed rampantly in hospitals across India,” the letter said.

Families of patients run from pillar to post for getting plasma, which is in short supply. The desperation of patients and their families is understandable because they like to try the best for their loved ones, when a doctor has prescribed this, the public health professionals said.

In the plasma therapy, antibodies from the blood of a patient who has recovered from COVID-19 are used to treat serious patients.

They said ICMR guidelines are not based on the existing evidence.

They cited the ICMR-PLACID trial which was the world’s first randomised controlled trial on convalescent plasma in 39 public and private hospitals across India.

It found “convalescent plasma was not associated with a reduction in progression to severe COVID-19 or all-cause mortality. This trial has high generalisability and approximates convalescent plasma use in real-life settings with limited laboratory capacity.”

The large trial of 11,588 patients found no difference in death or proportion of patients discharged from hospital, the clinicians said.

Even for those patients who were not on ventilation initially, there was no difference “in the proportion meeting the composite endpoint of progression to invasive mechanical ventilation or death,” they pointed out.

The health professionals added that the PlasmAr trial in Argentina concluded that there is no significant difference in “clinical status or overall mortality between patients treated with convalescent plasma and those who received placebo.”

“Current research evidence unanimously indicates that there is no benefit offered by convalescent plasma for treatment of COVID-19. However, it continues to be prescribed rampantly in hospitals across India,” they said.

Udayavani is now on Telegram. Click here to join our channel and stay updated with the latest news.

Top News

‘New tagline given for Karnataka is God’s Living Country’

M’luru cooker blast: Islamic preacher Zakir had tweeted about ‘suicide bomb’ hours after the incident

Gujarat polls: Modi, Kejriwal to address rallies in Surat

Karnataka Excels Under Ayushman Bharat Digital Mission: Sudhakar

Rain interrupts play in second ODI

Four girls drown in Kitwad Falls in Karnataka

Defeat of scholars in debate led to withdrawal of ‘jizya’ tax in Shah Jahan era: RSS chief


Related Articles More

Vitamin B12 deficiency is a common health problem that can have serious consequences – but doctors often overlook it

Doctors at KMC Manipal remove largest stone from woman’s urinary tract

Latest study in mice paves way for developing universal flu vaccine

We’re told to ‘eat a rainbow’ of fruit and vegetables. Here’s what each colour does in our body

Another Alzheimer’s drug fails in late-stage trials – what now?

MUST WATCH

Deepotsava at Shri Durga Adishakti temple

Girija Surgicals nebulizer vedio

KL Rahul Visit Kukke Subrahmanya Temple

Police commissioner N.Shahsikumar statement about viral video

CCTV Footage about mangaluru incident


Latest Additions

New legislation soon for administrative decentralization of varsities: Dr Ashwathnarayan

BJP will form stable govt on its own in HP: Party’s state unit chief Suresh Kashyap

‘New tagline given for Karnataka is God’s Living Country’

Cong seeks to bolster hold on key MP region with Rahul yatra; BJP launches counter campaign

M’luru cooker blast: Islamic preacher Zakir had tweeted about ‘suicide bomb’ hours after the incident

Thanks for visiting Udayavani

You seem to have an Ad Blocker on.
To continue reading, please turn it off or whitelist Udayavani.